Novel hybrid treatment planning approach for irradiation a pediatric craniospinal axis

Christian Ziemann; Florian Cremers; Laura Motisi; Dirk Albers; Miller MacPherson; Dirk Rades

doi:10.1016/j.meddos.2023.08.011

Novel hybrid treatment planning approach for irradiation a pediatric craniospinal axis

Med Dosim. 2023 Oct 3:S0958-3947(23)00076-6. doi: 10.1016/j.meddos.2023.08.011. Online ahead of print.

Authors

Christian Ziemann¹, Florian Cremers², Laura Motisi³, Dirk Albers⁴, Miller MacPherson⁵, Dirk Rades²

Affiliations

¹ Department of Radiotherapy, University Medical Center Schleswig Holstein/Campus Luebeck, Luebeck, Germany. Electronic address: christian.ziemann@uksh.de.
² Department of Radiotherapy, University Medical Center Schleswig Holstein/Campus Luebeck, Luebeck, Germany.
³ Department of Radiation Oncology, University Hospital Zürich, Zürich, Suisse.
⁴ Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁵ University of Ottawa, The Ottawa Hospital, Department of Radiology, Radiation Oncology, and Medical Physics, Ottawa, Canada.

PMID: 37798155
DOI: 10.1016/j.meddos.2023.08.011

Abstract

This study presents a new treatment planning approach merging 3D-CRT and VMAT fields into a hybrid treatment plan (HybTP), in order to achieve an optimum dose coverage of the planning target volume (PTV) and protection of OAR. Craniospinal axis irradiation (CSI) treated with 3D conformal radiotherapy (3D-CRT) is associated with high doses to the heart and eye lenses but provides better sparing of lungs and kidneys compared to volumetric modulated arc therapy (VMAT). VMAT treatment spares eye lenses and the heart, but lungs and kidneys are not as effective as 3D-CRT. Thus, a combination of both techniques (HybTP) may be optimal in sparing all these organs at risk (OAR). The results of HybTP are compared with helical tomotherapy (HT), intensity modulated radio therapy (IMRT), VMAT, and 3D-CRT plans. Hybrid, HT, VMAT, IMRT, and 3D-CRT treatment plans for a male child (age 6 years) with medulloblastoma were created and compared. A total dose of 35.2 Gy (PTV) with a dose per fraction of 1.6 Gy was prescribed. The following dose acceptance criteria were defined: The plans were compared regarding dose homogeneity index (HI) and conformity index (CI), PTV coverage, (particularly at cribriform plate) and doses at OARs. Best conformity was achieved with HT (CI = 0.98) followed by VMAT (CI = 0.96), IMRT (CI = 0.91), HybTP (CI = 0.86), and 3D-CRT (CI = 0.83). The homogeneity index varied marginally. For both HT and IMRT the HI was 0.07, and for 3D-CRT, VMAT and HybTP the HI was between 0.13 and 0.15. The cribriform plate was sufficiently covered by HybTP, VMAT, and 3D-CRT. The dose acceptance criteria for OARs were met by HT and HybTP. VMAT did not meet the criteria for lung (D_mean = right 10.4 Gy/left 10.2 Gy), 3D-CRT did not meet the criteria for eye lenses (D_max = right 32.3 Gy/left 33.1), and heart (V₂₅≈44%) and IMRT did not meet the criteria for lung (D_mean = right 11.1 Gy/left 11.2 Gy) and eye lenses (D_max = right 12.2 Gy/left 13.1). HybTP meets all defined acceptance criteria and has proved to be a reasonable alternative for CSI. With HybTP that combines VMAT at the brain and heart with 3D-CRT posterior spinal fields (to spare lungs and kidneys), both appropriate coverage of the PTV and sparing of OAR can be achieved.

Keywords: Craniospinal axis irradiation; Hybrid treatment; Medulloblastoma.

Publication types

Review